BridgeBio, Kyowa Kirin Partner with Upfront Payment of $100 M for an Exclusive License

 - BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan

- BridgeBio to receive upfront payment of USD 100 million with royalties up to the high-twenties percent, with additional milestone-based payments

- Infigratinib is a once daily oral treatment option under development for achondroplasia, which was well-tolerated and demonstrated potentially best-in-class efficacy in PROPEL 2, a Phase 2 study in children with achondroplasia

- PROPEL 3, a Phase 3 study of infigratinib in achondroplasia is underway globally outside of Japan with the first child dosed in December 2023

- Infigratinib adds to Kyowa Kirin’s successful portfolio in the therapeutic areas of bone & mineral diseases

https://www.biospace.com/article/releases/bridgebio-pharma-and-kyowa-kirin-announce-partnership-with-an-upfront-payment-of-100-million-for-an-exclusive-license-on-infigratinib-in-skeletal-dysplasias-in-japan/